Cue biopharma to present at the jmp securities hematology and oncology summit

Boston, nov. 22, 2023 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of t cell engagers to selectively modulate tumor-specific t cells, announced today that it will take part in a fireside chat at the jmp securities hematology and oncology summit being held virtually from december 5-6, 2023.

CUE Ratings Summary

CUE Quant Ranking